ArticleJournal of inflammation research2025
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Neglected kingdoms: the gut virome, mycobiome and their role in inflammatory bowel disease.Gut microbes · 2026Review
- Metabolic and neuroimmune control of rheumatoid arthritis: therapeutic implications of FXR and α7-nAChR axes.Inflammopharmacology · 2026Review
- Targeting the Gut Microbiota-Bile Acid-FXR Axis: The Therapeutic Mechanism of Yudantong Decoction in Cholestatic Liver Disease.Current medical science · 2026Article
- Article
- Macrophage pyroptosis in inflammatory bowel disease: mechanistic insights, pathological roles and treatment strategies.Frontiers in immunology · 2026Review
- Article
- Macrophages: emerging targets for ulcerative colitis.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ulcerative colitis (UC), a typical inflammatory bowel disease (IBD), is pathologically defined by mucosal inflammation confined to the colonic mucosa. Methods: A murine model of colitis was established through administration of dextran sulfate sodium (DSS), followed by oral gavage with either SbS or the control Sabouraud dextrose broth (SDB) culture medium. The FXR activation, NLRP3 inflammasome inhibition, and macrophage pyroptosis were evaluated both in vivo and in vitro. The effects of SbS in activating FXR, suppressing NLRP3 inflammasome and alleviating the colitis were assessed. Results: SbS ameliorated symptoms of DSS-induced colitis. Our data demonstrated that SbS elicited activation of FXR and concomitantly suppressed NLRP3 expression within the colonic tissue samples. Additionally, SbS was further observed to suppress the expression of cleaved caspase-1, a key effector protein in pyroptosis process, within the F4/80 Conclusion: SbS demonstrated a beneficial effect in alleviating UC by modulating the FXR-NLRP3 signaling pathway, thereby mitigating macrophage pyroptosis. This discovery presents new insights into effects of Sb on alleviating UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.